Tuberculosis is one of the world’s deadliest diseases:
it infects one third of the world’s population in developing countries and the high costs, long duration and poor compliance with the therapy, may lead to the development of multi-drug resistant bacterial strains, that make much harder to eradicate this disease.
STRITUVAD project aims to develop computer simulations to test the efficacy of new therapies, significantly reducing costs and duration of human clinical trials.